Tempest Therapeutics IncNASDAQ:TPST
- LAST PRICE3.1450
- TODAY'S CHANGE (%)-0.0250 (-0.7886%)
- Bid / Lots3.1400/ 4
- Ask / Lots3.1500/ 1
- Open / Previous Close3.1600 / 3.1700
- Day Range
- 52 Week Range
- Volume217,884
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TPST |
|---|---|---|
| 09:32 ET | 2475 | 3.1589 |
| 09:34 ET | 1100 | 3.15 |
| 09:36 ET | 500 | 3.16 |
| 09:38 ET | 250 | 3.16 |
| 09:39 ET | 2364 | 3.1989 |
| 09:41 ET | 5400 | 3.185 |
| 09:43 ET | 13099 | 3.2476 |
| 09:45 ET | 3770 | 3.244 |
| 09:48 ET | 4818 | 3.235 |
| 09:50 ET | 7700 | 3.24 |
| 09:52 ET | 368 | 3.2288 |
| 09:54 ET | 400 | 3.22 |
| 09:56 ET | 171 | 3.2112 |
| 09:59 ET | 1317 | 3.2 |
| 10:01 ET | 400 | 3.195 |
| 10:03 ET | 7799 | 3.1725 |
| 10:06 ET | 8700 | 3.16 |
| 10:08 ET | 200 | 3.15 |
| 10:10 ET | 3200 | 3.1479 |
| 10:12 ET | 858 | 3.13 |
| 10:14 ET | 2280 | 3.14 |
| 10:15 ET | 200 | 3.14 |
| 10:17 ET | 1600 | 3.1418 |
| 10:19 ET | 168 | 3.144 |
| 10:21 ET | 353 | 3.14 |
| 10:24 ET | 20770 | 3.12 |
| 10:26 ET | 197 | 3.12 |
| 10:28 ET | 2000 | 3.13 |
| 10:30 ET | 1800 | 3.14 |
| 10:32 ET | 1568 | 3.145 |
| 10:33 ET | 200 | 3.13 |
| 10:37 ET | 1740 | 3.1523 |
| 10:42 ET | 1101 | 3.16 |
| 10:46 ET | 3802 | 3.18 |
| 10:48 ET | 1794 | 3.15 |
| 10:50 ET | 16005 | 3.2 |
| 10:51 ET | 295 | 3.18 |
| 10:53 ET | 2284 | 3.1804 |
| 10:57 ET | 1115 | 3.17 |
| 11:00 ET | 300 | 3.17 |
| 11:02 ET | 300 | 3.15 |
| 11:04 ET | 100 | 3.15 |
| 11:06 ET | 200 | 3.15 |
| 11:08 ET | 633 | 3.16 |
| 11:09 ET | 111 | 3.17 |
| 11:11 ET | 8919 | 3.15 |
| 11:13 ET | 714 | 3.16 |
| 11:15 ET | 5200 | 3.16 |
| 11:18 ET | 7720 | 3.1575 |
| 11:22 ET | 1900 | 3.16 |
| 11:24 ET | 450 | 3.15 |
| 11:26 ET | 2700 | 3.15 |
| 11:27 ET | 3500 | 3.16 |
| 11:29 ET | 5100 | 3.16 |
| 11:31 ET | 1900 | 3.15 |
| 11:36 ET | 2479 | 3.1501 |
| 11:38 ET | 100 | 3.15 |
| 11:40 ET | 540 | 3.14 |
| 11:42 ET | 6535 | 3.13 |
| 11:44 ET | 200 | 3.13 |
| 11:45 ET | 100 | 3.13 |
| 11:47 ET | 350 | 3.13 |
| 11:49 ET | 2600 | 3.14 |
| 11:51 ET | 100 | 3.13 |
| 11:54 ET | 200 | 3.13 |
| 11:56 ET | 100 | 3.13 |
| 11:58 ET | 800 | 3.13 |
| 12:00 ET | 200 | 3.13 |
| 12:02 ET | 806 | 3.15 |
| 12:03 ET | 1100 | 3.15 |
| 12:05 ET | 100 | 3.155 |
| 12:07 ET | 5700 | 3.18 |
| 12:09 ET | 100 | 3.17 |
| 12:20 ET | 2797 | 3.1699 |
| 12:21 ET | 100 | 3.17 |
| 12:23 ET | 700 | 3.1661 |
| 12:30 ET | 450 | 3.16 |
| 12:36 ET | 200 | 3.1601 |
| 12:38 ET | 7458 | 3.135 |
| 12:39 ET | 1093 | 3.135 |
| 12:41 ET | 100 | 3.135 |
| 12:43 ET | 2676 | 3.1406 |
| 12:48 ET | 200 | 3.145 |
| 12:50 ET | 500 | 3.145 |
Apr 9, 2024
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 4, 2024
Mar 20, 2024
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 6:49AM ET on Wednesday Mar 20, 2024 by Dow Jones
6:49AM ET on Wednesday Mar 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tempest Therapeutics Inc | 70.3M | -1.6x | --- |
AN2 Therapeutics Inc | 70.9M | -0.9x | --- |
Corvus Pharmaceuticals Inc | 69.1M | -2.5x | --- |
Cognition Therapeutics Inc | 71.8M | -2.2x | --- |
Regencell Bioscience Holdings Ltd | 67.9M | -8.9x | --- |
Landos Biopharma Inc | 67.8M | -6.2x | --- |
Company Information
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Contact Information
- Headquarters
- 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
- Phone
- 415-798-8589
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Michael Raab
- President, Chief Executive Officer, Director
- Stephen Brady
- Executive Vice President, Chief Medical Officer, Head of Research and Development
- Samuel Whiting
- Vice President - Finance, Corporate Secretary
- Nicholas Maestas
- Independent Director
- Geoffrey Nichol
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.58 |
EPS | $-1.96 |
Book Value | $1.21 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
